DGX vs MYGN
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions.
Side-by-side fundamentals
| Metric | DGX | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $237.12 | $5.54 | |
| Market cap | $26.2B | $530M | |
| P/E as of 2026-10-20 | 25.17 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | 7.96 | n/a | |
| Net margin FY2025, SEC XBRL | +9.0% | -44.4% | DGX higher |
| Gross margin FY2025, SEC XBRL | n/a | +69.9% | |
| Operating margin FY2025, SEC XBRL | +14.1% | -47.0% | DGX higher |
| ROE FY2025, SEC XBRL | +13.8% | -99.4% | DGX higher |
| ROA FY2025, SEC XBRL | +6.1% | -51.8% | DGX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.75 | 0.40 | MYGN lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.8% | -1.6% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | +6.7% | MYGN higher |
| Dividend yield as of 2026-09-03 | +1.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | DGX higher |
| Beta as of 2026-09-03 | 0.15 | 1.14 | |
| 1-year return as of 2026-10-20 close | +24.5% | -29.9% | DGX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.